Significant Profitability and Cash Flow Improvement
Full-year adjusted EBITDA increased 21.3% to $408.0M (6.8% margin); operating profit improved by $100.0M and operating margin expanded 190 bps year-over-year. Free cash flow improved 276% to $187.0M and operating cash flow rose ~77%.
Strong Q4 Margin and EBITDA Performance
Q4 adjusted EBITDA rose 10.6% (+$10.0M) to $106.0M with margin expanding 82 bps to 7.0%. Operating profit in the quarter increased $14.0M (83%) while gross margin expanded 37 bps to 38.3% and SG&A leveraged 62 bps to 36.2% of sales.
Improved Balance Sheet and Reduced Leverage
Net debt to EBITDA improved from ~4.2x at the start of the year to 3.0x at year-end. Ending cash was $257.0M (up $91.0M year-over-year) and the company voluntarily paid down $95.0M of debt; refinancing moved to a more optimal fixed/floating mix and extended maturities to 2031.
Gross Margin Expansion and Cost Discipline
Full-year gross margin rate expanded 66 bps to 38.7% and SG&A leverage improved 124 bps to 36.6% as the company disciplined assortment, reduced unprofitable sales, and lowered inventory (Q4 ending inventory down 9.7% versus a 2.4% decline in Q4 sales).
Clear Strategic Roadmap and Customer Segmentation
Completed 'Petco North Star' customer segmentation and identified the 'Passionate Explorers' cohort. Management presented a four-pillar 'Reach for the Sky' growth plan (product newness, services at scale, trusted store experience, integrated omnichannel) with measurable initiatives.
Concrete Product and Omni Initiatives to Drive Repeat Visits
Planned execution includes adding over 1,000 freezers in 2026, ~25 new brands/flavors and more frequent product drops, expanding own brands (currently ~20% of sales) which carry higher margins, relaunching loyalty, and enabling repeat-delivery customers to pick up orders in-store.
Services and Store Ecosystem as Differentiators
Wholly owned services (approx. 300 vet hospitals, grooming in all stores, training) were highlighted as a durable moat. Productivity optimizations were completed in 2025 and underutilized hospital locations (~25) are being targeted for improvement; ROIC improved by three percentage points in 2025.
Forward-Looking Financial Targets
FY2026 guidance targets net sales flat to +1.5% and adjusted EBITDA of $415.0M–$430.0M. Q1 guide: net sales down 1% to flat and adjusted EBITDA of $92.0M–$94.0M. Full-year capex ~$140.0M, net interest expense ~ $125.0M, and D&A ~ $200.0M.